Vertex Pharmaceuticals (NASDAQ:VRTX) Announces Quarterly Earnings Results

Vertex Pharmaceuticals (NASDAQ:VRTX) announced its earnings results on Monday. The pharmaceutical company reported $4.76 EPS for the quarter, topping the consensus estimate of $3.66 by $1.10, Briefing.com reports. The firm had revenue of $2.69 billion for the quarter, compared to the consensus estimate of $2.58 billion. Vertex Pharmaceuticals had a return on equity of 21.91% and a net margin of 36.68%. The business’s quarterly revenue was up 13.3% compared to the same quarter last year. During the same period in the previous year, the business earned $2.67 EPS. Vertex Pharmaceuticals updated its FY 2024 guidance to EPS.

Vertex Pharmaceuticals Stock Up 1.9 %

VRTX opened at $410.24 on Wednesday. The company’s 50-day moving average price is $408.02 and its two-hundred day moving average price is $400.75. The company has a quick ratio of 3.78, a current ratio of 3.99 and a debt-to-equity ratio of 0.02. Vertex Pharmaceuticals has a twelve month low of $320.01 and a twelve month high of $448.40. The stock has a market cap of $106.03 billion, a price-to-earnings ratio of 29.53, a PEG ratio of 1.89 and a beta of 0.39.

Insider Buying and Selling

In other Vertex Pharmaceuticals news, COO Stuart A. Arbuckle sold 4,295 shares of the company’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $420.24, for a total transaction of $1,804,930.80. Following the sale, the chief operating officer now directly owns 75,718 shares of the company’s stock, valued at $31,819,732.32. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, EVP Ourania Tatsis sold 354 shares of the business’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $425.70, for a total transaction of $150,697.80. Following the sale, the executive vice president now directly owns 55,804 shares in the company, valued at approximately $23,755,762.80. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Stuart A. Arbuckle sold 4,295 shares of the firm’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $420.24, for a total value of $1,804,930.80. Following the completion of the transaction, the chief operating officer now owns 75,718 shares of the company’s stock, valued at approximately $31,819,732.32. The disclosure for this sale can be found here. In the last quarter, insiders have sold 12,381 shares of company stock valued at $5,203,249. 0.20% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages have commented on VRTX. Canaccord Genuity Group reaffirmed a “sell” rating and set a $371.00 target price on shares of Vertex Pharmaceuticals in a report on Friday, April 12th. Cantor Fitzgerald reissued an “overweight” rating and issued a $440.00 price objective on shares of Vertex Pharmaceuticals in a research note on Tuesday, February 20th. UBS Group dropped their price objective on Vertex Pharmaceuticals from $498.00 to $466.00 and set a “buy” rating on the stock in a research note on Wednesday, April 17th. Maxim Group downgraded Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Finally, StockNews.com raised Vertex Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, May 3rd. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $432.18.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.